Emerald Advisers LLC boosted its holdings in Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) by 57.3% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 244,633 shares of the company's stock after purchasing an additional 89,088 shares during the quarter. Emerald Advisers LLC owned about 0.60% of Keros Therapeutics worth $3,873,000 at the end of the most recent quarter.
A number of other large investors have also recently bought and sold shares of KROS. Point72 Asia Singapore Pte. Ltd. raised its holdings in shares of Keros Therapeutics by 36.7% in the third quarter. Point72 Asia Singapore Pte. Ltd. now owns 3,844 shares of the company's stock valued at $223,000 after buying an additional 1,033 shares during the last quarter. Handelsbanken Fonder AB increased its position in Keros Therapeutics by 11.3% in the 4th quarter. Handelsbanken Fonder AB now owns 10,800 shares of the company's stock valued at $171,000 after acquiring an additional 1,100 shares during the period. China Universal Asset Management Co. Ltd. increased its position in Keros Therapeutics by 19.0% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 8,589 shares of the company's stock valued at $136,000 after acquiring an additional 1,372 shares during the period. Point72 DIFC Ltd raised its stake in Keros Therapeutics by 9.8% during the 3rd quarter. Point72 DIFC Ltd now owns 19,255 shares of the company's stock valued at $1,118,000 after acquiring an additional 1,715 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank lifted its position in Keros Therapeutics by 59.0% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,371 shares of the company's stock worth $312,000 after acquiring an additional 1,994 shares during the period. Institutional investors and hedge funds own 71.56% of the company's stock.
Keros Therapeutics Stock Down 1.8 %
Shares of KROS traded down $0.20 on Friday, hitting $10.79. 277,817 shares of the stock traded hands, compared to its average volume of 696,696. Keros Therapeutics, Inc. has a 1 year low of $9.78 and a 1 year high of $72.37. The firm has a market capitalization of $437.66 million, a P/E ratio of -2.07 and a beta of 1.39. The stock's 50 day moving average is $11.15 and its two-hundred day moving average is $34.58.
Keros Therapeutics (NASDAQ:KROS - Get Free Report) last released its quarterly earnings data on Wednesday, February 26th. The company reported ($1.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.36) by $0.22. Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. The company had revenue of $3.04 million during the quarter, compared to the consensus estimate of $37.32 million. Research analysts forecast that Keros Therapeutics, Inc. will post -4.74 EPS for the current year.
Wall Street Analyst Weigh In
KROS has been the subject of several analyst reports. Wells Fargo & Company cut their price target on Keros Therapeutics from $28.00 to $26.00 and set an "overweight" rating for the company in a research note on Thursday, February 27th. BTIG Research downgraded shares of Keros Therapeutics from a "buy" rating to a "neutral" rating in a research report on Thursday, December 12th. Wedbush downgraded shares of Keros Therapeutics from an "outperform" rating to a "neutral" rating and lowered their target price for the company from $47.00 to $15.00 in a report on Friday, January 17th. Cantor Fitzgerald cut shares of Keros Therapeutics from an "overweight" rating to a "neutral" rating in a report on Tuesday, January 21st. Finally, Truist Financial lowered their price objective on Keros Therapeutics from $100.00 to $43.00 and set a "buy" rating on the stock in a report on Monday, December 23rd. Six equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $42.33.
Check Out Our Latest Report on KROS
Keros Therapeutics Company Profile
(
Free Report)
Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.
Further Reading
Before you consider Keros Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Keros Therapeutics wasn't on the list.
While Keros Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
